[go: up one dir, main page]

PL2317998T3 - Kombinacja kwasu fulwowego i antybiotyku - Google Patents

Kombinacja kwasu fulwowego i antybiotyku

Info

Publication number
PL2317998T3
PL2317998T3 PL09757983.3T PL09757983T PL2317998T3 PL 2317998 T3 PL2317998 T3 PL 2317998T3 PL 09757983 T PL09757983 T PL 09757983T PL 2317998 T3 PL2317998 T3 PL 2317998T3
Authority
PL
Poland
Prior art keywords
fulvic acid
antibiotic combination
antibiotic
combination
fulvic
Prior art date
Application number
PL09757983.3T
Other languages
English (en)
Inventor
Antonio Celestino Fernandes
Constance Elizabeth Medlen
Stephen Leivers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2317998T3 publication Critical patent/PL2317998T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
PL09757983.3T 2008-06-05 2009-06-04 Kombinacja kwasu fulwowego i antybiotyku PL2317998T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ZA200804901 2008-06-05

Publications (1)

Publication Number Publication Date
PL2317998T3 true PL2317998T3 (pl) 2016-11-30

Family

ID=40887008

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09757983.3T PL2317998T3 (pl) 2008-06-05 2009-06-04 Kombinacja kwasu fulwowego i antybiotyku

Country Status (8)

Country Link
US (1) US8445452B2 (pl)
EP (1) EP2317998B1 (pl)
CN (1) CN102099027B (pl)
BR (1) BRPI0913586A8 (pl)
PL (1) PL2317998T3 (pl)
RU (1) RU2505295C2 (pl)
WO (1) WO2009147635A1 (pl)
ZA (1) ZA201008680B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914966D0 (en) * 2009-08-27 2009-09-30 Natracine Uk Ltd Fulvic acid compositions and their use
IN2014DN07194A (pl) * 2012-03-07 2015-04-24 Natracine Uk Ltd
CN113813304A (zh) * 2020-06-18 2021-12-21 陈信行 腐植酸山苍子复方及其制程
CN111616358A (zh) * 2020-06-20 2020-09-04 田劭军 一种用于提高免疫力的组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204368A (en) * 1990-05-25 1993-04-20 National Energy Council Bacteriostatic and bacteriocidal method using fulvic acid derivatives
EP1700599B1 (en) * 1998-10-08 2008-10-08 Pfeinsmith Limited Fulvic acid and its use in the treatment of candida infections
CN1120820C (zh) * 1999-08-12 2003-09-10 河南省科学院生物研究所 健植液肥
US8114910B2 (en) * 2006-05-02 2012-02-14 Pfeinsmith S.A. (Pty) Ltd. Acidic composition
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方

Also Published As

Publication number Publication date
US8445452B2 (en) 2013-05-21
CN102099027A (zh) 2011-06-15
CN102099027B (zh) 2012-12-12
RU2010154511A (ru) 2012-07-20
BRPI0913586A2 (pt) 2015-10-27
BRPI0913586A8 (pt) 2018-03-13
US20110207687A1 (en) 2011-08-25
RU2505295C2 (ru) 2014-01-27
EP2317998B1 (en) 2016-04-20
ZA201008680B (en) 2012-03-28
EP2317998A1 (en) 2011-05-11
WO2009147635A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
IL209141A0 (en) Novel substituted pyridin-2-ones and pyridazin-3-ones
IL210153A0 (en) Nutrigenomics methods and compositions
EP2483221A4 (en) FERTILIZER COMPOSITIONS AND METHOD THEREFOR
IL206929A0 (en) Dilator
IL212822A0 (en) Anti-cxcr1 compositions and methods
PT2374452T (pt) Composição de nutrientes
GB0819530D0 (en) Methods and compositions
GB0820262D0 (en) Microorganisms
GB0808575D0 (en) Compilign and linking
PL2294024T3 (pl) Emalie i nośniki
GB0821928D0 (en) Antibiotic nanomaterial
GB2455636B (en) Trailers
ZA201008680B (en) Fulvic acid and antibiotic combination
EP2320888A4 (en) LAIDLOMYCIN COMPOSITIONS AND METHODS
GB0810099D0 (en) Final assemblies
GB0811250D0 (en) Methods and compositions
GB0813359D0 (en) Halfin and/or platerfin
GB0817114D0 (en) Composter
AU2009904474A0 (en) Composting
GB0914966D0 (en) Fulvic acid compositions and their use
GB0820320D0 (en) Biomaterials
AU2009901914A0 (en) Improvements in Composting
AU2009905993A0 (en) Nitrogen fertiliser use-efficiency
AU2008900345A0 (en) Improved Fertiliser
GB0810835D0 (en) Stake out